nach oben

Journal of Gastroenterology

Erschienen in:

01.02.2012 | Review

The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models

verfasst von: Hiroko Oshima, Masanobu Oshima

Erschienen in: Journal of Gastroenterology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Accumulating evidence has indicated that inflammatory responses are important for cancer development. Epidemiological studies have shown that regular use of non-steroidal anti-inflammatory drugs (NSAIDs) reduces the risk of colon cancer development. Subsequently, mouse genetic studies have shown that cyclooxygenase (COX)-2, one of the target molecules of NSAIDs, and its downstream product, prostaglandin E₂ (PGE₂), play an important role in gastrointestinal tumorigenesis. Bacterial infection stimulates the Toll-like receptor (TLR)/MyD88 pathway in tumor tissues, which leads to the induction of COX-2 in stromal cells, including macrophages. Induction of the COX-2/PGE₂ pathway in tumor stroma is important for the development and maintenance of an inflammatory microenvironment in gastrointestinal tumors. In such a microenvironment, tumor-associated macrophages express proinflammatory cytokines, including tumor necrosis factor (TNF)-α and interleukin (IL)-6, and these cytokines, respectively, activate the nuclear factor (NF)-κB and Stat3 transcription factors in epithelial cells, as well as in stromal cells. Recent mouse studies have uncovered the role of such an inflammatory network in the promotion of gastrointestinal tumor development. Genetically engineered and chemically induced mouse tumor models which mimic sporadic or inflammation-associated tumorigenesis were used in these studies. In this review article, we focus on mouse genetic studies using these tumor models, which have contributed to the elucidation of the molecular mechanisms associated with the inflammatory network in gastrointestinal tumors, and we also discuss the role of each pathway in cancer development. The involvement of immune cells such as macrophages, mast cells, and regulatory T cells in tumor promotion is also discussed.

Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248:171–83.PubMedCrossRef

Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–44.PubMedCrossRef

Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15:425–30.PubMedCrossRef

Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M. Tobacco smoke promotes lung tumorigenesis by triggering IKKβ-and JNK1-dependent inflammation. Cancer Cell. 2010;17:89–97.PubMedCrossRef

Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197–208.PubMedCrossRef

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.PubMedCrossRef

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.PubMedCrossRef

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.PubMedCrossRef

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.PubMedCrossRef

10.

Thun MJ, Namboodiri MM, CW Jr Heath. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593–6.PubMedCrossRef

11.

Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333:609–14.PubMedCrossRef

12.

Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10:181–93.PubMedCrossRef

13.

Wang D, DuBois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene. 2010;29:781–8.PubMedCrossRef

14.

Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci USA. 1995;92:4482–6.PubMedCrossRef

15.

Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 1989;247:322–4.CrossRef

16.

Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet. 1992;1:229–33.PubMedCrossRef

17.

Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutations occur early during colorectal tumorigenesis. Nature. 1992;359:235–7.PubMedCrossRef

18.

Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/β-catenine/TCF pathway in colorectal cancer. Cancer Sci. 1998;58:1130–4.

19.

Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–35.PubMedCrossRef

20.

van Hogezand RA, Eichhorn RF, Choudry A, Veenendaal RA, Lamers BHW. Malignancies in inflammatory bowel disease: fact or fiction? Scand J Gastroenterol. 2002;235:48–53.CrossRef

21.

Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 2003;94:965–73.PubMedCrossRef

22.

Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. Novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98:694–702.PubMed

23.

Erdman SE, Poutahidis T, Tomczak M, Rogers AB, Cormier K, Plank B, et al. CD4⁺ CD25⁺ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol. 2003;162:691–702.PubMedCrossRef

24.

Erdman SE, Rao VP, Poutahidis T, Ihrig MM, Ge Z, Feng Y, et al. CD4⁺ CD25⁺ regulatory T lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res. 2003;63:6042–50.PubMed

25.

Clements WM, Wang J, Saranaik A, Kim OJ, MacDonald J, Fenoglio-Preiser C, et al. β-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res. 2002;62:3503–6.PubMed

26.

Oshima H, Matusnaga A, Fujimura T, Tsukamoto T, Taketo MM, Oshima M. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E₂ pathway. Gastroenterology. 2006;131:1086–95.PubMedCrossRef

27.

Correa P. Helicobactor pylori infection and gastric cancer. Cancer Epidemiol Biomark Prev. 2003;12:238s–41s.

28.

Fu S, Ramanujam KS, Wong A, Fantry GT, Drachenberg CB, James SP, et al. Increased expression and cyclooxygenase 2 in Helicobactor pylori gastritis. Gastroenterology. 1999;116:1319–29.PubMedCrossRef

29.

Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J. 2004;23:1669–78.PubMedCrossRef

30.

Oshima H, Oguma K, Du YC, Oshima M. Prostaglandin E₂, Wnt, and BMP in gastric tumor mouse models. Cancer Sci. 2009;100:1779–85.PubMedCrossRef

31.

Oshima H, Oshima M. Mouse models of gastric tumors: Wnt activation and PG E₂ induction. Pathol Int. 2010;60:599–607.PubMedCrossRef

32.

Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313–6.PubMedCrossRef

33.

Oshima M, Taketo MM. COX selectivity and animal models for colon cancer. Curr Pharm Des. 2002;8:1021–34.PubMedCrossRef

34.

Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc ^Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87:803–9.PubMedCrossRef

35.

Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, et al. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 2000;60:4705–8.PubMed

36.

Myung S, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA. 2006;103:12098–102.PubMedCrossRef

37.

Al-Salihi MA, Pearman AT, Doan T, Reichert EC, Rosenberg DW, Prescott SM, et al. Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression. Cancer Lett. 2009;273:225–32.PubMedCrossRef

38.

Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Natumiya S, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc ^Δ716 knockout mice. Nat Med. 2001;7:1048–51.PubMedCrossRef

39.

Seno H, Oshima M, Ishikawa TO, Oshima H, Takaku K, Chiba T, et al. Cyclooxygenase 2- and prostaglandin E₂ receptor EP₂-dependent angiogenesis in Apc ^Δ716 mouse intestinal polyps. Cancer Res. 2002;62:506–11.PubMed

40.

Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, et al. Prostaglandin E₂ promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferators-activated receptor δ. Cancer Cell. 2004;6:285–95.PubMedCrossRef

41.

Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E₂ promotes colon cancer cell growth through a G_s-axin-β-catenin signaling axis. Science. 2005;310:1504–10.PubMedCrossRef

42.

van Rees BP, Sivula A, Thoren S, Yokozaki H, Jalobsson PJ, Offerhaus GJ, Ristimaki A. Expression of microsomal prostaglandin E synthase-1 in intestinal gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer. 2003;107:551–6.PubMedCrossRef

43.

Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ, Subbaramaiah K. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res. 2001;7:2669–74.PubMed

44.

Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP, et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res. 2008;68:3251–9.PubMedCrossRef

45.

Nakanishi M, Menoret A, Tanaka T, Miyamoto S, Montrose DC, Vella AT, Rosenberg DW. Selective PGE₂ suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev Res. 2011;4:1198–208.CrossRef

46.

Ristimaki A, Honkanen N, Jankaka H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276–80.PubMed

47.

Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, van Rees BP, Rio MC, et al. Cyclooxygenase-2 and gastric carcinogenesis. APMIS. 2003;111:915–25.PubMedCrossRef

48.

Oshima H, Popivanova BK, Oguma K, Kong D, Ishikawa TO, Oshima M. Activation of epidermal growth factor receptor signaling by the prostaglandin E₂ receptor EP4 pathway during gastric tumorigenesis. Cancer Sci. 2011;102:713–9.PubMedCrossRef

49.

Oshima H, Hioki K, Popivanova BK, Oguma K, van Rooijen N, Ishikawa TO, Oshima M. Prostaglandin E₂ signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology. 2011;140:596–607.PubMedCrossRef

50.

Sonoshita M, Takaku K, Oshima M, Sugihara K, Taketo MM. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res. 2002;62:6846–9.PubMed

51.

Hull MA, Booth JK, Tisbury A, Scott N, Bonifer C, Markham AF, Coletta PL. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br J Cancer. 1999;79:1399–405.PubMedCrossRef

52.

Takeda H, Sonoshita M, Oshima H, Sugihara K, Chulada PC, Langenbach R, et al. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res. 2003;63:4872–7.PubMed

53.

Miyoshi H, Nakau M, Ishikawa T, Seldin FM, Oshima M, Taketo MM. Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice. Cancer Res. 2002;62:2261–6.PubMed

54.

Tamai Y, Nakajima R, Ishikawa T, Takaku K, Seldin MF, Taketo MM. Colonic hamartoma development by anomalous duplication in Cdx2 knockout mice. Cancer Res. 1999;59:2965–70.PubMed

55.

Kitamura T, Kometani K, Hashida H, Matsunaga A, Miyoshi H, Hosogi H, et al. SMAD4-deficient intestinal tumors recruit CCR1⁺ myeloid cells that promote invasion. Nat Genet. 2007;39:467–75.PubMedCrossRef

56.

Takeda H, Miyoshi H, Tamai Y, Oshima M, Taketo MM. Simultaneous expression of COX-2 and mPGES-1 in mouse gastrointestinal hamartomas. Br J Cancer. 2004;90:701–4.PubMedCrossRef

57.

Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118:229–41.PubMedCrossRef

58.

Pull SL, Doherty JM, Mills JC, Gordon JI, Stappenbeck TS. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci USA. 2005;102:99–104.PubMedCrossRef

59.

Fukuta M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, et al. Cox-2 is regulated by toll like receptor-4 (TLR-4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology. 2006;131:862–77.CrossRef

60.

Fukuta M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007;133:1869–81.CrossRef

61.

Hernandez Y, Sotolongo J, Breglio K, Conduah D, Chen A, Xu R, et al. The role of prostaglandin E₂ (PGE₂) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia. BMC Gastroenterol. 2010;10:82.

62.

Fukata M, Hernandez Y, Conduah D, Cohen J, Chen A, Breglio K, et al. Innate immune signaling by toll-like receptor-4 (TLR-4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis. 2009;15:997–1006.PubMedCrossRef

63.

Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein Myd88. Science. 2007;317:124–7.PubMedCrossRef

64.

Lee SH, Hu LL, Gonzalez-Navajas J, Seo GS, Shen C, Brick J, et al. ERK activation drives intestinal tumorigenesis in Apc ^Min/+ mice. Nat Med. 2010;16:665–70.PubMedCrossRef

65.

Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9:57–63.PubMedCrossRef

66.

Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest. 1996;98:2076–85.PubMedCrossRef

67.

Morteau O, Morham SG, Sellon R, Dieleman LA, Langenbach R, Smithies O, et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest. 2000;105:469–78.PubMedCrossRef

68.

Ishikawa TO, Herschman HR. Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis. 2010;31:729–36.PubMedCrossRef

69.

Ishikawa TO, Oshima M, Herschman HR. Cox-2 deletion in myeloid and endothelial cells, but not in epithelial cells, exacerbates murine colitis. Carcinogenesis. 2011;32:417–26.PubMedCrossRef

70.

Balkwill F. Tumor necrosis factor and cancer. Nat Rev Cancer. 2009;9:361–71.PubMedCrossRef

71.

Karin M, Greten FR. NF-κB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–59.PubMedCrossRef

72.

Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285–96.PubMedCrossRef

73.

Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, et al. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. 2008;118:560–70.

74.

Popivanova BK, Kostadinova FI, Furuichi K, Shamekh MM, Kondo T, Wada T, et al. Blocking of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res. 2009;69:7884–92.PubMedCrossRef

75.

Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 1989;169:1485–90.PubMedCrossRef

76.

Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, Gounairi F, et al. Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci USA. 2007;104:19977–82.PubMedCrossRef

77.

Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-κB functions as a tumor promoter in inflammation-associated cancer. Nature. 2004;431:461–6.PubMedCrossRef

78.

Oshima M, Oshima H, Matsunaga A, Taketo MM. Hyperplastic gastric tumors with spasmolytic polypeptide-expressing metaplasia caused by tumor necrosis factor-α-dependent inflammation in cyclooxygenase-2/microsomal prostaglandin E synthase-1 transgenic mice. Cancer Res. 2005;65:9147–51.PubMedCrossRef

79.

Kishimoto T. Interleukin-6: from basic science to medicine—40 years in immunology. Annu Rev Immunol. 2005;23:1–21.PubMedCrossRef

80.

Heikkila K, Ebrahim S, Lawlor DA. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer. 2008;44:937–45.PubMedCrossRef

81.

Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. gp130-mediated STAT3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009;15:91–102.PubMedCrossRef

82.

Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103–13.PubMedCrossRef

83.

He G, Karin M. NF-κB and STAT3-key players in liver inflammation and cancer. Cell Res. 2011;21:159–68.PubMedCrossRef

84.

Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell. 2011;19:429–31.PubMedCrossRef

85.

Tebbutt NC, Giraud AS, Inglese M, Jennkins B, Waring P, Clay FJ, et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med. 2002;8:1089–97.PubMedCrossRef

86.

Jenkins BJ, Grail D, Nheu T, Najdovska M, Wang B, Waring P, et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling. Nat Med. 2005;11:845–52.PubMedCrossRef

87.

Judd LM, Bredin K, Kalantzis A, Jenkins BJ, Ernst M, Giraud AS. STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. Gastroenterology. 2006;131:1073–85.PubMedCrossRef

88.

Howlett M, Giraud AS, Lescesen H, Jackson CB, Kalantzis A, van Driel IR, et al. The interleukin-6 family cytokine interleukin-11 regulates homeostatic epithelial cell turnover and promotes gastric tumor development. Gastroenterology. 2009;136:976–77.

89.

Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51.PubMedCrossRef

90.

Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889–85

91.

DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, et al. CD4⁺ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16:91–102.PubMedCrossRef

92.

Nakanishi Y, Nakatsuji M, Seno H, Ishizu S, Akitake-kawano R, Kanda K, et al. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in Apc ^Min/+ mouse polyps. Carcinogenesis. 2011;32:1333–9.PubMedCrossRef

93.

Oguma K, Oshima H, Aoki M, Uchio R, Naka K, Nakamura S, et al. Activated macrophages promote Wnt signaling through tumour necrosis factor-a in gastric tumour cells. EMBO J. 2008;27:1671–81.PubMedCrossRef

94.

Erdman SE, Sohn JJ, Rao VP, Nambiar PR, Ge Z, Fox JG, Schauer DB. CD4⁺CD25⁺ regulatory lymphocytes induce regression of intestinal tumors in Apc ^Min/+ mice. Cancer Res. 2005;65:3998–4004.PubMedCrossRef

95.

Gounaris E, Blatner NR, Dennis K, Magnusson F, Gurish MF, Strom TB, et al. T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res. 2009;69:5490–6.PubMedCrossRef

96.

Colombo MP, Piconese S. Polyps wrap mast cells and Treg within tumorigenic tentacles. Cancer Res. 2009;69:5619–22.PubMedCrossRef

97.

Chae WJ, Gibson TF, Zelterman D, Hao L, Henegariu O, Bothwell ALM. Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci USA. 2010;107:5540–4.PubMedCrossRef

Titel: The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models
verfasst von: Hiroko Oshima
Masanobu Oshima
Publikationsdatum: 01.02.2012
Verlag: Springer Japan
Erschienen in: Journal of Gastroenterology / Ausgabe 2/2012
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-011-0523-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Serum gamma-glutamyltransferase level is associated with serum superoxide dismutase activity and metabolic syndrome in a Japanese population

Long-term administration of PPI reduces treatment failures after esophageal variceal band ligation: a randomized, controlled trial

Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cells

Association of gastric acid and mucus secretion level with low-dose aspirin-induced gastropathy

Comparisons of symptoms reported by elderly and non-elderly patients with GERD